Get started
Author

Lourdes Ruiz‐Ortega

Observed names: L. Ruiz-Ortega, L. Ruiz‐Ortega, Lourdes Ruiz-Ortega
ORCID: 0000-0003-3636-3367
Observed ORCID: 0000-0003-3636-3367
OpenAlex ID: A5028869212
Low HDL and high triglycerides predict COVID-19 severity
2021 · Lluís Masana, Eudald Correig, et al. · Scientific Reports · 187
PDF
The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening Rate
2022 · Laia Aceituno, Juan Bañares, et al. · Frontiers in Medicine · 11
Circulating exhausted CD8+ effector memory cells differentiate immune checkpoint inhibitor-induced liver injury from other acute immune-mediated liver injuries
2026 · Stuart Astbury, Edmond Atallah, et al. · Journal for ImmunoTherapy of Cancer · 6
PDF
Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: A retrospective case-control study
2022 · Juan Bañares, Ramiro Manzano-Nuñez, et al. · Frontiers in Endocrinology · 6
Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma
2026 · L. Aceituno, C. Magyar, et al. · Alimentary Pharmacology & Therapeutics · 5
Evaluating the safety of immune checkpoint inhibitors prior to liver transplant.
2025 · Laia Aceituno, Christian Tibor Josef Magyar, et al. · Journal of Clinical Oncology · 2
PDF
JAK Inhibitors for Autoimmune Hepatitis: One Swallow Does Not Make a Summer
2025 · Juan Carlos Ruiz‐Cobo, Lourdes Ruiz‐Ortega, et al. · Liver International · 2
PDF
250P Liver Toxicity (LT) in patients (pts) with ER-positive HER2-negative metastatic breast cancer (MBC) treated with first-line Cyclin-Dependent Kinase 4/6 inhibitors (CDKi)
2023 · K.S. Vega Cano, P. Mascaro, et al. · ESMO Open · 2
PDF
Zinc supplementation to improve prognosis in patients with compensated advanced chronic liver disease: a multicenter, randomized, double-blind, placebo-controlled clinical trial
2024 · Juan Bañares, Laia Aceituno, et al. · Hepatology Communications · 1
TOP-139 Combination of liver steatosis and premenopausal is a risk factor for DILI due to cyclin-dependent kinase 4/6 inhibitors as first-line treatment for metastatic breast cancer
2024 · Kreina Sharela Vega-Cano, Lourdes Ruiz-Ortega, et al. · Journal of Hepatology
473P Predictive factors for drug-induced liver injury in patients with ER-positive HER2-negative metastatic breast cancer treated with first-line cyclin-dependent kinase 4/6 inhibitors
2023 · K.S. Vega Cano, G. Villacampa Javierre, et al. · Annals of Oncology
Works count: 11
Citation count: 222
H-index: 5
I10-index: 2
Year
Topic
Type